BioSpace News Archive

Alnylam Pharmaceuticals, Inc. announced today that it has achieved full patient enrollment in its HELIOS-B Phase 3 study of vutrisiran, an investigational RNAi therapeutic in development for the treatment of cardiomyopathy in patients with transthyretin-mediated (ATTR) amyloidosis.

Dicerna Pharmaceuticals, Inc. today reported its financial results for the quarter ended June 30, 2021 and provided a corporate update.

Cipher Pharmaceuticals Inc. today announced it will release its Q2 2021 financial results on Thursday, August 12 , 2021. The company will hold a conference call on Friday, August 13, 2021 to discuss the results.

Nuvo Pharmaceuticals Inc. dba Miravo to Host Conference Call/Audio Webcast August 9th at 11:00 a.m. ET

Epizyme, Inc., a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies announced its Chief Executive Officer succession plan, with industry veteran Grant Bogle succeeding Robert Bazemore, as President and CEO.

Avinger, Inc. today announced the submission of a 510(k) application to the U.S. Food & Drug Administration (FDA) for its new Lightbox 3 imaging console.

Epizyme today reported its second quarter 2021 financial results and provided a business update.

Tempest Therapeutics, Inc., a clinical-stage oncology company developing potentially first-in-class therapeutics that combine both targeted and immune-mediated mechanisms, announced the appointment of Ronit Simantov, M.D., a seasoned and accomplished industry veteran as well as hematology and oncology expert, to the company’s board of directors.

BioLife Solutions, Inc. (Nasdaq: BLFS) (“BioLife” or the “Company”), a leading developer and supplier of class-defining bioproduction products and services for cell and gene therapies and the broader biopharma market, today announced that it has entered into a definitive agreement to acquire all remaining outstanding shares of privately held Sexton Biotechnologies, Inc.,

Harmony Biosciences Holdings, Inc. (“Harmony”) (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients living with rare neurological diseases, today announced the acquisition of HBS-102 (formerly CSTI-100),